Correlation Engine 2.0
Clear Search sequence regions

  • female (2)
  • humans (1)
  • hyponatremia (5)
  • lung disease (1)
  • patient (2)
  • seizures (2)
  • Sizes of these terms reflect their relevance to your search.

    Cyclophosphamide is an alkylating agent used in routine pulmonary practice, particularly in the management of connectivitis-related diffuse interstitial lung disease. Common side effects are gastrointestinal disorders and immunosuppression, and a sudden and exceptional adverse effect is severe hyponatremia. A 78-year-old female patient treated for NSIP-OP in the context of an anti-synthetase syndrome was treated with Cyclophosphamide 15mg/kg. Twenty-four hours after the end of the infusion, she was diagnosed at home in a coma with comitial seizures. Biological assessment revealed severe hyponatremia at 109 mmol/l with blood hypo-osmolarity. The patient's condition rapidly improved following correction of the ionic disorder. Hyponatremia induced by low-dose Cyclophosphamide is a rare but serious adverse effect that requires special attention. Copyright © 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.


    M Delin, J-M Gilardoni, M Cremoni, M Ben Hayoun, G Keirle, J Pradelli, J Benzaquen, S Leroy. The role of hyponatremia in the rapid onset of coma after Cyclophosphamide]. Revue des maladies respiratoires. 2022 Jun;39(6):571-574

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 35659457

    View Full Text